{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:31:02Z","timestamp":1765701062346,"version":"3.48.0"},"reference-count":30,"publisher":"BMJ","issue":"9","funder":[{"name":"French Ministry of Health"},{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,8,2]]},"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Osteoarthritis (OA) pathophysiology is driven in part by joint inflammation. Resveratrol has in vitro anti-inflammatory properties. We aim to assess the efficacy of oral resveratrol for knee pain at 3 months in people with knee OA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We will conduct a randomised double-blind placebo-controlled trial. Overall, 164 individuals with knee OA fulfilling 1986 American College of Rheumatology criteria will be recruited in three tertiary care centres in France and randomised to receive oral resveratrol, 40\u2009mg (two caplets) two times per day for 1\u2009week, then 20\u2009mg (one caplet) two times per day or a matching placebo for a total of 6 months. Randomisation will be centralised and stratified by centre. The allocation ratio of assignments will be 1:1. The primary outcome will be the mean change from baseline in knee pain on a self-administered 11-point pain Numeric Rating Scale at 3 months. Secondary outcomes will be the mean change in knee pain at 6 months, the function subscore of the Western Ontario and McMaster Universities Arthritis Index score, patient global assessment, proportion of responders according to the Osteoarthritis Research Society International\u2013Outcome Measures in Rheumatology criteria at 3 and 6 months, and self-reported number of intra-articular injections of corticosteroids or hyaluronic acid and consumption of analgesics and non-steroidal anti-inflammatory drugs since the last contact. Other interventions will be allowed and self-reported. Adherence will be monitored by capsule counts and a booklet and adverse events recorded at 3 and 6 months. Statisticians, treating physicians and participants will be blinded to the allocated treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>\n                      The oral resveratrol in knee osteoarthritis (ARTHROL) trial has been authorised by the\n                      <jats:italic>AgenceNationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9<\/jats:italic>\n                      and ethics were approved by the\n                      <jats:italic>Comit\u00e9 deProtection des Personnes \u00cele-de-France<\/jats:italic>\n                      III. The findings of the study will be published in a peer-reviewed journal and disseminated at conferences. The design of ARTHROL will warrant the translation of its findings into clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02905799\">NCT02905799<\/jats:ext-link>\n                      . Pre-results. First received: 14 September 2016. Last updated: 16 September 2016. Status: not yet recruiting.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-017652","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T20:10:19Z","timestamp":1506802219000},"page":"e017652","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Evolution of pain at 3 months by oral resveratrol in knee osteoarthritis (ARTHROL): protocol for a multicentre randomised double-blind placebo-controlled trial"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct02905799","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christelle","family":"Nguyen","sequence":"first","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine, Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Paris, France"},{"name":"Service de R\u00e9\u00e9ducation et de R\u00e9adaptation de l\u2019Appareil Locomoteur et des Pathologies du Rachis, AP-HP, H\u00f4pitaux Universitaires Paris Centre-Groupe Hospitalier Cochin, Paris, France"},{"name":"INSERM UMR 1124, Laboratoire de Pharmacologie, Toxicologie et Signalisation Cellulaire, Facult\u00e9 des Sciences Fondamentales et Biom\u00e9dicales, Centre Universitaire des Saints-P\u00e8res, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Boutron","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine, Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Paris, France"},{"name":"AP-HP, H\u00f4pital H\u00f4tel-Dieu, Centre d\u2019\u00c9pid\u00e9miologie Clinique, Paris, France"},{"name":"INSERM UMR 1153, Centre de Recherche \u00c9pid\u00e9miologie et Statistique, Sorbonne Paris Cit\u00e9, METHODS Team, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Baron","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine, Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Paris, France"},{"name":"INSERM UMR 1153, Centre de Recherche \u00c9pid\u00e9miologie et Statistique, Sorbonne Paris Cit\u00e9, METHODS Team, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Coudeyre","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Physique et de R\u00e9adaptation, Centre Hospitalo-Universitaire de Clermont-Ferrand, INRA, Universit\u00e9 Clermont Auvergne, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Berenbaum","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Pierre et Marie-Curie, Sorbonne Paris Cit\u00e9, Paris, France"},{"name":"Service de Rhumatologie, AP-HP, H\u00f4pital Saint-Antoine, Paris, France"},{"name":"INSERM UMR 938, DHU i2B, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Poiraudeau","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine, Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Paris, France"},{"name":"Service de R\u00e9\u00e9ducation et de R\u00e9adaptation de l\u2019Appareil Locomoteur et des Pathologies du Rachis, AP-HP, H\u00f4pitaux Universitaires Paris Centre-Groupe Hospitalier Cochin, Paris, France"},{"name":"INSERM UMR 1153, Centre de Recherche \u00c9pid\u00e9miologie et Statistique, Sorbonne Paris Cit\u00e9, ECaMO Team, Paris, France"},{"name":"Institut F\u00e9d\u00e9ratif de Recherche sur le Handicap, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Rannou","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de M\u00e9decine, Sorbonne Paris Cit\u00e9, Universit\u00e9 Paris Descartes, Paris, France"},{"name":"Service de R\u00e9\u00e9ducation et de R\u00e9adaptation de l\u2019Appareil Locomoteur et des Pathologies du Rachis, AP-HP, H\u00f4pitaux Universitaires Paris Centre-Groupe Hospitalier Cochin, Paris, France"},{"name":"INSERM UMR 1124, Laboratoire de Pharmacologie, Toxicologie et Signalisation Cellulaire, Facult\u00e9 des Sciences Fondamentales et Biom\u00e9dicales, Centre Universitaire des Saints-P\u00e8res, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"key":"2025121400271660000_7.9.e017652.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"2025121400271660000_7.9.e017652.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60243-2"},{"key":"2025121400271660000_7.9.e017652.3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090633","article-title":"The burden of musculoskeletal conditions","volume":"9","author":"Palazzo","year":"2014","journal-title":"PLoS One"},{"key":"2025121400271660000_7.9.e017652.4","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1056776"},{"key":"2025121400271660000_7.9.e017652.5","doi-asserted-by":"crossref","unstructured":"Roberts E , Delgado Nunes V , Buckner S , et al . Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016;75.doi:10.1136\/annrheumdis-2014-206914","DOI":"10.1136\/annrheumdis-2014-206914"},{"key":"2025121400271660000_7.9.e017652.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019881","article-title":"What is new for an old molecule? Systematic review and recommendations on the use of resveratrol","volume":"6","author":"Vang","year":"2011","journal-title":"PLoS One"},{"key":"2025121400271660000_7.9.e017652.7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/nu9010045","article-title":"Resveratrol, potential therapeutic interest in joint disorders: a critical narrative Review","volume":"9","author":"Nguyen","year":"2017","journal-title":"Nutrients"},{"key":"2025121400271660000_7.9.e017652.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.23799"},{"key":"2025121400271660000_7.9.e017652.9","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e3181883883"},{"key":"2025121400271660000_7.9.e017652.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2006.11.012"},{"key":"2025121400271660000_7.9.e017652.11","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4"},{"key":"2025121400271660000_7.9.e017652.12","doi-asserted-by":"publisher","DOI":"10.1007\/s12263-010-0179-5"},{"key":"2025121400271660000_7.9.e017652.13","doi-asserted-by":"publisher","DOI":"10.1186\/ar2850"},{"key":"2025121400271660000_7.9.e017652.14","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/j.1745-7254.2008.00880.x","article-title":"Resveratrol protects bone marrow mesenchymal stem cell derived chondrocytes cultured on chitosan-gelatin scaffolds from the inhibitory effect of interleukin-1beta","volume":"29","author":"Lei","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"2025121400271660000_7.9.e017652.15","doi-asserted-by":"publisher","DOI":"10.1186\/ar3127"},{"key":"2025121400271660000_7.9.e017652.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2008.05.029"},{"key":"2025121400271660000_7.9.e017652.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2657-0"},{"key":"2025121400271660000_7.9.e017652.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem368"},{"key":"2025121400271660000_7.9.e017652.19","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/ajcn\/68.6.1208","article-title":"Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium","volume":"68","author":"Ferrero","year":"1998","journal-title":"Am J Clin Nutr"},{"key":"2025121400271660000_7.9.e017652.20","doi-asserted-by":"publisher","DOI":"10.1006\/taap.2000.9122"},{"key":"2025121400271660000_7.9.e017652.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-004-1341-6"},{"key":"2025121400271660000_7.9.e017652.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1720-y"},{"key":"2025121400271660000_7.9.e017652.23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/jor.22859","article-title":"Intra-articular resveratrol injection prevents osteoarthritis progression in a mouse model by activating SIRT1 and thereby silencing HIF-2\u03b1","volume":"33","author":"Li","year":"2015","journal-title":"J Orthop Res"},{"key":"2025121400271660000_7.9.e017652.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2013.01.008"},{"key":"2025121400271660000_7.9.e017652.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"2025121400271660000_7.9.e017652.26","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200900437"},{"key":"2025121400271660000_7.9.e017652.27","first-page":"799","article-title":"Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III","volume":"24","author":"Bellamy","year":"1997","journal-title":"J Rheumatol"},{"key":"2025121400271660000_7.9.e017652.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2015.03.005"},{"key":"2025121400271660000_7.9.e017652.29","first-page":"1833","article-title":"Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee","volume":"15","author":"Bellamy","year":"1988","journal-title":"J Rheumatol"},{"key":"2025121400271660000_7.9.e017652.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2004.02.001"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-017652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:27:24Z","timestamp":1765700844000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-017652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,29]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1136\/bmjopen-2017-017652"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-017652","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}